CU 13001
Alternative Names: CU-13001Latest Information Update: 28 Sep 2024
At a glance
- Originator Acurex Biosciences
- Class Antiparkinsonians; Small molecules
- Mechanism of Action 15-lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 24 Jul 2024 Preclinical trials in Parkinson's disease in USA (PO) prior to July 2024 (Acurex Biosciences Pipeline, July 2024)
- 24 Jul 2024 Acurex Biosciences announces intention to submit an Investigational New Drug Application (IND) for Parkinson's disease in 2025 (Acurex Biosciences Pipeline, July 2024)
- 24 Jul 2024 Acurex Biosciences plans an IND-enabling study for Parkinson's disease (Acurex Biosciences Pipeline, July 2024)